S 5316: BINSA Act

S 5316 in plain English: The BINSA Act would address national security concerns related to financial ties between U.S. pharmaceutical companies and Chinese biotechnology firms, which totaled approximately $136,000,000,000 in 2025. The bill has been referred to the Senate Committee on Banking, Housing, and Urban Affairs.

Stated purpose

The bill aims to add biotechnology — including pharmaceutical products, biological products, and therapeutic compounds — to the list of technologies that face special restrictions and reporting requirements when American investors deal with certain foreign entities, particularly those connected to China, under the Defense Production Act of 1950.

Key points

• Targets approximately $136,000,000,000 in financial ties between U.S. pharmaceutical and Chinese biotechnology firms as of 2025
• Addresses national security concerns over the rapid transfer of pharmaceutical interests to Chinese firms

Arguments supporters make

• Biotechnology has military and civilian uses, and letting U.S. money and drug-development know-how flow to China could make America dangerously dependent on a foreign rival for medicines — just as happened with semiconductors.
• Cross-border licensing deals with Chinese biotech firms totaled roughly $136 billion in 2025, showing the scale of intellectual property transfer that could undermine U.S. pharmaceutical leadership.
• Applying the same outbound investment screening that already covers semiconductors and AI to biotech closes a major gap and treats comparable national security risks consistently.

Arguments opponents make

• Restricting biotech investment and licensing could slow global collaboration on drug development, raising costs and potentially delaying treatments that American patients need.
• Broad definitions of "biotechnology" may sweep in routine business deals that pose no real security risk, creating compliance burdens for smaller companies and researchers.
• Unilateral U.S. restrictions without allied coordination could push Chinese firms to partner with European or other foreign companies instead, limiting American influence without reducing China's access to the technology.

Tradeoffs

Tightening oversight of biotech deals with China may reduce national security risks from technology transfer, but it could also restrict the cross-border partnerships and capital flows that help fund drug discovery and lower medicine costs for Americans.

Current status in Congress: In committee.

NewsClear — neutral news & congressional tracking · Bill of the Week